Your session is about to expire
← Back to Search
Arfolitixorin for Colorectal Cancer (AGENT Trial)
AGENT Trial Summary
This trial is testing a new drug to see if it's better than the current standard of care for treating advanced colorectal cancer.
- Colorectal Cancer
AGENT Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowAGENT Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 3 trial • 490 Patients • NCT03750786AGENT Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Does Arfolitixorin have any dangerous side effects?
"Arfolitixorin falls into Phase 3 of clinical trials, meaning that there is already some data supporting its efficacy and multiple rounds of tests affirming its safety. Consequently, our team rates Arfolitixorin's safety as a 3."
What conditions does Arfolitixorin typically help alleviate?
"Arfolitixorin is most effective in combating methotrexate toxicity. Additionally, this medication can help treat normochromic anemia, advanced esophageal cancers, and folate deficiencies."
Are there any geographic restrictions to this research study?
"Out of the 28 participating clinics, this trial is currently recruiting patients. A few locations where these medical centres can be found are Brampton, San Antonio and Gatineau. If you wish to enroll in the study, try and select a clinic that is close to your residence to limit travel."
Yes, what other scientific investigations have included Arfolitixorin?
"Right now, there are 279 clinical trials being conducted for Arfolitixorin. 86 of those live clinical trials are in Phase 3. The majority of studies for Arfolitixorin are based in Melbourne, Victoria, but there are 16136 total locations running trials globally."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger